Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Clin Exp Vaccine Res ; 2(1): 69-70, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23596594

ABSTRACT

Based on the action plan "Ensuring a stable supply of National Immunization Program vaccines and sovereignty of biopharmaceutical products," Korea Food and Drug Administration (KFDA) has made efforts to develop vaccines in the context of self reliance and to protect public health. Along with the recognized infrastructures for clinical trials, clinical trials for vaccines have also gradually been conducted at multinational sites as well as at local sites. KFDA will support to expand six to eleven kinds of vaccines by 2017. In accordance with integrated regulatory system, KFDA has promoted clinical trials, established national lot release procedure, and strengthened good manufacturing practices inspection and post marketing surveillance. Against this backdrop, KFDA will support the vaccine development and promote excellent public health protection.

2.
Arch Pharm Res ; 30(5): 616-23, 2007 May.
Article in English | MEDLINE | ID: mdl-17615682

ABSTRACT

It is well known that endocrine disruptors (EDs) act as anti-estrogenic agents and affect the function of reproductive organ. EDs are also thought to affect thyroid hormone (TH) system which is important for biological functions such as growth, development and metabolism. However, it is still not clear how EDs are able to regulate TH receptor (TR)-mediated functions. In this study, therefore, the modulatory effects of representative EDs such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyl (Aroclor 1254) and bisphenol A (BPA) were examined using TR-expressing GH3 cells (a rat pituitary gland epithelial tumor cell line) activated by triiodothyronine (T3). EDs tested significantly blocked T3 binding to TR in a dose-dependent manner. Biochemical characterization by Scatchard and Lineweaver-Burk plot analyses indicated that TCDD and aroclor 1254 bound to TH receptors in a competitive inhibitory manner, whereas BPA bound to TH receptors in a non-competitive pattern. The different inhibitory mode of action by EDs was also found in regulating TR-mediated production of prolactin (PRL). Aroclor 1254 exposure for 48 h enhanced T3-mediated PRL production, but BPA down-regulated. These results suggest that the EDs (TCDD, Aroclor 1254 and BPA) could differentially bind to TR and distinctly regulate the action of TR function, even though EDs are structurally similar.


Subject(s)
Endocrine Disruptors/toxicity , Receptors, Thyroid Hormone/drug effects , Animals , Benzhydryl Compounds , Cell Line, Tumor , Cell Survival/drug effects , Phenols/pharmacology , Polychlorinated Dibenzodioxins/toxicity , Prolactin/biosynthesis , Rats , Receptors, Thyroid Hormone/physiology , Triiodothyronine/pharmacology
3.
Biochem Biophys Res Commun ; 357(4): 903-9, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17466268

ABSTRACT

Neurotrophin-3 (NT-3) is well known to play an important role in facilitating neuronal survival and differentiation during development. However, the mechanisms by which neurotrophin-3 promotes prolonged Akt/MAPK signaling at an early stage are not well understood. Here, we report that NT-3 works at an early stage of neuronal differentiation in mouse neural stem cells (NSCs). After treatment with NT-3 for 12h, more NSCs differentiated into neurons than did untreated cells. These findings demonstrated that stimulation with NT-3 causes NSCs to differentiate into neurons through a phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway and the phosphorylated extracellular signal-regulated kinase (ERK) pathway. In addition, treatment with NT-3 induced neurite outgrowth by specific phosphorylation of p38 MAPK, which was accompanied by neuronal differentiation. Taken together, these results suggest that NT-3, along with the Trk C receptors in NSCs, might lead to the survival and neuronal differentiation of NSCs via two distinct downstream signaling pathways at an early stage of neuronal differentiation.


Subject(s)
MAP Kinase Signaling System/physiology , Neurons/cytology , Neurons/metabolism , Neurotrophin 3/administration & dosage , Stem Cells/cytology , Stem Cells/metabolism , Animals , Cell Differentiation/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , MAP Kinase Signaling System/drug effects , Mice , Neurons/drug effects , Stem Cells/drug effects
4.
Pharmazie ; 62(12): 937-42, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18214347

ABSTRACT

Curcumin, the major yellow pigment in turmeric (Curcuma longa), is a well-documented naturally-occurring anti-oxidant with numerous pharmacological activities such as anti-inflammatory, anti-carcinogenic and anti-bacterial effects. In this study, curcumin's neuroprotective effect was carefully examined using a coculture system, based on reports that curcumin-containing plants are neuroprotective. Coculturing neuronal cells and activated microglial cells enhanced dopamine-induced neuronal cell death from 30% up to 50%. However, curcumin did not protect dopamine-directed neuronal cell death and sodium nitroprosside (SNP)-induced NO generation, but only blocked activated microglial cell-mediated neuronal cell damage under inflammatory conditions. Indeed, curcumin blocked the production of pro-inflammatory and cytotoxic mediators such as NO, TNF-alpha, IL-1alpha, and IL-6 produced from Abeta(25-35)/IFN-gamma- and LPS-stimulated microglia, in a dose-dependent manner. Therefore, our results suggest that curcumin-mediated neuroprotective effects may be mostly due to its anti-inflammatory effects.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Curcumin/pharmacology , Microglia/drug effects , Neuroprotective Agents , Animals , Antioxidants/pharmacology , Cell Death/drug effects , Cell Line , Cell Survival/drug effects , Coculture Techniques , Cytokines/biosynthesis , DNA Fragmentation/drug effects , Dopamine/pharmacology , Fluorescent Dyes , Indoles , Inflammation Mediators/metabolism , Microglia/metabolism , Neurons/drug effects , Nitrites/metabolism , Nitroprusside/pharmacology , Rats , Rats, Sprague-Dawley
5.
Arch Pharm Res ; 29(11): 1042-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17146974

ABSTRACT

Plasmid DNA vaccines encoding the hepatitis B virus (HBV) surface and hepatitis C virus (HCV) envelope antigens, respectively, were constructed, and attempt were made to find the possibility of a divalent vaccine against HBV and HCV. The expression of each plasmid in Cos-1 cells was confirmed using immunocytochemistry. To measure the induced immune response by these plasmids in vivo, female BALB/c mice were immunized intramuscularly with 100 microg of either both or just one of the plasmids. Anti-HBV and HCV-specific antibodies and related cytokines were evaluated to investigate the generation of both humoral and cellular immune responses. As a result, specific anti-HBV and anti-HCV serum antibodies from mice immunized with these plasmids were observed using immunoblot. The levels of IL-2 and RANTES showing a Th1 immune response were significantly increased, but there was no change in the level of IL-4 (Th2 immune response) in any of the immunized groups. Compared with each plasmid DNA vaccine, the combined vaccine elicited similar immune responses in both humoral and cell-mediated immunities. These results suggest that the combined DNA vaccine can induce not only comparable immunity experimentally without antigenic interference, but also humoral and Th1 dominant cellular immune responses. Therefore, they could serve as candidates for a simultaneous bivalent vaccine against HBV and HCV infections.


Subject(s)
Hepatitis B Surface Antigens/immunology , Hepatitis C Antigens/immunology , Immunity/drug effects , Animals , Blotting, Western , COS Cells , Cell Proliferation/drug effects , Chlorocebus aethiops , Cytokines/biosynthesis , Female , Fluorescent Antibody Technique , Hepatitis B Antibodies/analysis , Hepatitis C Antibodies/analysis , Immunization Schedule , Interleukin-4/biosynthesis , Mice , Mice, Inbred BALB C , Plasmids/immunology , Spleen/cytology , Vaccines, DNA/immunology , Viral Envelope Proteins/immunology
6.
Life Sci ; 79(21): 2022-31, 2006 Oct 19.
Article in English | MEDLINE | ID: mdl-16934299

ABSTRACT

Curcumin has been shown to exhibit anti-inflammatory, antimutagenic, and anticarcinogenic activities. However, the modulatory effect of curcumin on the functional activation of primary microglial cells, brain mononuclear phagocytes causing the neuronal damage, largely remains unknown. The current study examined whether curcumin influenced NO production in rat primary microglia and investigated its underlying signaling pathways. Curcumin decreased NO production in LPS-stimulated microglial cells in a dose-dependent manner, with an IC(50) value of 3.7 microM. It also suppressed both mRNA and protein levels of inducible nitric oxide synthase (iNOS), indicating that this drug may affect iNOS gene expression process. Indeed, curcumin altered biochemical patterns induced by LPS such as phosphorylation of all mitogen-activated protein kinases (MAPKs), and DNA binding activities of nuclear factor-kappaB (NF-kappaB) and activator protein (AP)-1, assessed by reporter gene assay. By analysis of inhibitory features of specific MAPK inhibitors, a series of signaling cascades including c-Jun N-terminal kinase (JNK), p38 and NF-kappaB was found to play a critical role in curcumin-mediated NO inhibition in microglial cells. The current results suggest that curcumin is a promising agent for the prevention and treatment of both NO and microglial cell-mediated neurodegenerative disorders.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Curcumin/pharmacology , Lipopolysaccharides/pharmacology , Microglia/drug effects , Nitric Oxide/biosynthesis , Animals , Blotting, Western , Cells, Cultured , Electrophoretic Mobility Shift Assay , Mice , Microglia/enzymology , Microglia/metabolism , Mitogen-Activated Protein Kinase Kinases/metabolism , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/genetics , RNA, Messenger/genetics , Rats , Reverse Transcriptase Polymerase Chain Reaction
7.
Bioelectromagnetics ; 25(4): 245-50, 2004 May.
Article in English | MEDLINE | ID: mdl-15114633

ABSTRACT

We investigated the premorbid behavioral changes produced by the administration of cocaine and acute exposure to extremely low frequency (ELF) magnetic field (MF) in the mouse. ICR mice received intraperitoneal injections of cocaine at two doses (65 and 70 mg/kg) and were subsequently exposed to one of eight ELF-MF fields (2, 3, 4, 8, 10, 15, 25, or 60 Hz) of about 20 G (2 mT) intensity immediately after injection. Twelve mice were used for each of applied cocaine dose and ELF-MF level. For a given dose of cocaine, the applied MF frequencies were randomly ordered, and blind tests were carried out in which the behavior observer did not know the frequencies of MF. The premorbid behaviors were defined in the ICR mice and their changes were observed over the exposure of various ELF-MFs. Our data show that the onset times of stop rearing and tonic-clonic seizure in the 4 Hz MF exposure group are significantly different from those of the sham group.


Subject(s)
Behavior, Animal/drug effects , Cocaine/toxicity , Magnetics , Animals , Dose-Response Relationship, Radiation , Male , Mice , Mice, Inbred ICR
8.
Bioconjug Chem ; 15(2): 326-32, 2004.
Article in English | MEDLINE | ID: mdl-15025528

ABSTRACT

Receptor-associated protein (RAP) is a ligand for all members of low-density lipoprotein (LDL) receptor families. RAP is internalized into cells via receptor-mediated endocytic trafficking, making it an attractive mechanism for efficient gene delivery. In this study, we have developed a gene delivery system using RAP as a targeting ligand. A RAP cDNA lacking a C-terminal heparin-binding domain was amplified by polymerase chain reaction (PCR) from a human liver cDNA library and was reamplified by using a primer containing a cysteine codon at its carboxyl end to facilitate its conjugation to polylysine (polyK). RAP was purified using a bacterial expression system and coupled to poly-D-lysine (PDL) or poly-L-lysine (PLL) of average MW 50 kDa via the heterobifunctional cross-linker SPDP. Using fluorescence-labeled RAP ligand, cellular uptake of the transfection complexes into HepG2 cells was shown to be highly efficient and more specific to PDL-conjugated RAP compared with PLL-conjugated one. Plasmid DNA containing a luciferase reporter gene was condensed with either RAP-PDL or RAP-PLL. In vitro transfection into HepG2 cells with RAP-PDL conjugate resulted in significantly higher luciferase expression levels in comparison to either nonconjugated PDL, or RAP-PLL, or LipofecAMINE/DNA complexes in the presence of 10% fetal bovine serum. Luciferase expression was inhibited by the addition of excess RAP. Treatment of the cells with Lovastatin, which inhibits HMG-Co reductase and increases expression of LDL receptor, stimulates luciferase expression, suggesting that the gene delivery is specifically mediated by LDL receptor. Thus, RAP-PDL conjugates have the potential to be used as a new nonviral gene delivery vector.


Subject(s)
Carcinoma, Hepatocellular/genetics , Gene Transfer Techniques , LDL-Receptor Related Protein-Associated Protein/genetics , Polylysine/genetics , Binding, Competitive , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , LDL-Receptor Related Protein-Associated Protein/metabolism , Lovastatin/pharmacology , Polylysine/metabolism , Transfection/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...